What is Embleema?
Embleema operates at the intersection of healthcare and enterprise software, providing a highly secure and configurable platform designed to unify electronic medical records, patient-reported outcomes, and real-time data streams. By facilitating non-interventional research, the company enables sponsors and research sites to accelerate the development of precision medicine. The platform is engineered to capture complex, multimodal patient data, which is essential for the generation of regulatory-grade real-world evidence. Through its streamlined workflows, Embleema effectively reduces the operational costs associated with disease-specific studies while maintaining rigorous compliance and transparency standards. This infrastructure is critical for modernizing how clinical data is managed, ensuring that patient engagement remains at the forefront of the research lifecycle.
How much funding has Embleema raised?
Embleema has raised a total of $3.7M across 1 funding round:
Series A
$3.7M
Series A (2019): $3.7M, investors not publicly disclosed
Key Investors in Embleema
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Embleema?
With this major enterprise-level funding, Embleema is poised to expand its market footprint and enhance its technological capabilities. The strategic focus will likely shift toward deepening the integration of its platform within global research networks and scaling its data management tools to accommodate larger, more complex clinical trials. By leveraging this capital, the company aims to further simplify the research process, ultimately reducing the time-to-market for life-saving therapies. As the demand for high-quality, real-world evidence continues to grow within the pharmaceutical and biotech industries, Embleema is strategically positioned to capture significant market share by providing the digital backbone necessary for the next generation of precision medicine initiatives.
See full Embleema company page
